Twist Bioscience Corp — Director's Dealing 2022

Mar 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2022-03-03

Reporting Person: THORBURN JAMES M (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-03	Common Stock	M	1517	$26.66	Acquired	48662	Direct
2022-03-03	Common Stock	M	2000	$23.33	Acquired	50662	Direct
2022-03-03	Common Stock	S	2107	$51.9646	Disposed	48555	Direct
2022-03-03	Common Stock	S	1230	$52.8060	Disposed	47325	Direct
2022-03-03	Common Stock	S	180	$53.68	Disposed	47145	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-03	Employee Stock Option (right to buy)	$26.66	M	1517	Disposed	2028-11-18	Common Stock (1517)	Direct
2022-03-03	Employee Stock Option (right to buy)	$23.33	M	2000	Disposed	2029-10-23	Common Stock (2000)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on August 24, 2021.

F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $51.46 to $52.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $52.47 to $53.35 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F4: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)

F5: 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

F6: 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.